Abstract Background Wild type RAS (RAS-wt) status is predictive of the activities of the anti-epidermal growth factor receptor (EGFR) monoclonal antibodies cetuximab (C) and panitumumab (P). We examined the impact of C and P on progression-free survival (PFS), overall survival (OS) and overall response rate (ORR) in advanced colorectal cancer (CRC) patients who have RAS-wt/BRAF-mutant (BRAF-mut) status. Methods Randomised trials that compared C or P plus chemotherapy (or C or P monotherapy) with standard therapy or best supportive care (BSC) were included. We used published hazard ratios (HRs) if they were available, or we derived treatment estimates from other survival data. Pooled estimates of the treatment efficacy of anti-EGFR-based therapy with C or P for the RAS-wt/BRAF-mut subgroup were calculated with the random-effect inverse variance weighted method. All statistical tests were two-sided. Results Nine phase III trials and one phase II trial (six first-line and two second-line trials, plus two trials involving chemorefractory patients), that included 463 RAS-wt/BRAF-mut CRC patients, were analysed. Overall, the addition of C or P treatment in the BRAF-mut subgroup did not significantly improve PFS (HR, 0.88; 95% confidence interval (CI), 0.67-1.14; p = 0.33), OS (HR, 0.91; 95% CI, 0.62-1.34; p = 0.63) and ORR (relative risk, 1.31; 95% CI 0.83-2.08, p = 0.25) compared with control regimens. Conclusions C- or P-based therapy did not increase the benefit of standard therapy or the BSC in RAS-wt/BRAF-mut CRC patients. These findings support BRAF mutation assessment before initiation of treatment with anti-EGFR monoclonal antibodies.

Predictive role of BRAF mutations in patients with advanced colorectal cancer receiving cetuximab and panitumumab : a meta-analysis / F. Pietrantonio, F. Petrelli, A. Coinu, M. Di Bartolomeo, K. Borgonovo, C. Maggi, M. Cabiddu, R. Iacovelli, I. Bossi, V. Lonati, M. Ghilardi, F. De Braud, S. Barni. - In: EUROPEAN JOURNAL OF CANCER. - ISSN 0959-8049. - 51:5(2015 Mar), pp. 9390.587-9390.594. [10.1016/j.ejca.2015.01.054]

Predictive role of BRAF mutations in patients with advanced colorectal cancer receiving cetuximab and panitumumab : a meta-analysis

F. Pietrantonio
Primo
;
K. Borgonovo;C. Maggi;F. De Braud
Penultimo
;
2015-03

Abstract

Abstract Background Wild type RAS (RAS-wt) status is predictive of the activities of the anti-epidermal growth factor receptor (EGFR) monoclonal antibodies cetuximab (C) and panitumumab (P). We examined the impact of C and P on progression-free survival (PFS), overall survival (OS) and overall response rate (ORR) in advanced colorectal cancer (CRC) patients who have RAS-wt/BRAF-mutant (BRAF-mut) status. Methods Randomised trials that compared C or P plus chemotherapy (or C or P monotherapy) with standard therapy or best supportive care (BSC) were included. We used published hazard ratios (HRs) if they were available, or we derived treatment estimates from other survival data. Pooled estimates of the treatment efficacy of anti-EGFR-based therapy with C or P for the RAS-wt/BRAF-mut subgroup were calculated with the random-effect inverse variance weighted method. All statistical tests were two-sided. Results Nine phase III trials and one phase II trial (six first-line and two second-line trials, plus two trials involving chemorefractory patients), that included 463 RAS-wt/BRAF-mut CRC patients, were analysed. Overall, the addition of C or P treatment in the BRAF-mut subgroup did not significantly improve PFS (HR, 0.88; 95% confidence interval (CI), 0.67-1.14; p = 0.33), OS (HR, 0.91; 95% CI, 0.62-1.34; p = 0.63) and ORR (relative risk, 1.31; 95% CI 0.83-2.08, p = 0.25) compared with control regimens. Conclusions C- or P-based therapy did not increase the benefit of standard therapy or the BSC in RAS-wt/BRAF-mut CRC patients. These findings support BRAF mutation assessment before initiation of treatment with anti-EGFR monoclonal antibodies.
BRAF mutation; Cetuximab; Colorectal cancer; Meta-analysis; Panitumumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Cetuximab; Chi-Square Distribution; Colorectal Neoplasms; DNA Mutational Analysis; Disease Progression; Disease-Free Survival; Humans; Molecular Targeted Therapy; Odds Ratio; Precision Medicine; Predictive Value of Tests; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; Receptor, Epidermal Growth Factor; Risk Factors; Time Factors; Treatment Outcome; ras Proteins; Mutation; Cancer Research; Oncology; Medicine (all)
Settore MED/06 - Oncologia Medica
Article (author)
File in questo prodotto:
File Dimensione Formato  
1-s2.0-S0959804915000982-main.pdf

accesso riservato

Tipologia: Publisher's version/PDF
Dimensione 793.45 kB
Formato Adobe PDF
793.45 kB Adobe PDF   Visualizza/Apri   Richiedi una copia
Pubblicazioni consigliate

Caricamento pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: http://hdl.handle.net/2434/426870
Citazioni
  • ???jsp.display-item.citation.pmc??? 175
  • Scopus 341
  • ???jsp.display-item.citation.isi??? 329
social impact